Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications

Current Opinion in Neurology

Volumn 24, Issue 3, 2011, Pages 224-229

  Stadelmann, Christine ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

cytoskeletal alterations; mitochondrial damage; multiple sclerosis; neurodegeneration; T cell infiltration

Indexed keywords

ACID SENSING ION CHANNEL BLOCKING AGENT; ION TRANSPORT AFFECTING AGENT; PROTEIN INHIBITOR; SODIUM CALCIUM EXCHANGE PROTEIN INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BRAIN MITOCHONDRION; CELLULAR IMMUNITY; CYTOSKELETON; DEMYELINATION; DISABILITY; DISEASE COURSE; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NONHUMAN; T LYMPHOCYTE;

AXONS; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; MITOCHONDRIA; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 79955582720     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328346056f     Document Type: Article

References (67)

1. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008; 7:615-625.
2. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58:65-70. (Pubitemid 32053209)
3. Aboul-Enein F, Krssak M, Hoftberger R, et al. Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One 2010; 5:e11625.
4. Schirmer L, Antel JP, Bruck W, Stadelmann C. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol 2010 [Epub ahead of print].
5. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206:165-171. (Pubitemid 36143722)
6. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119 (Pt 3):701-708. (Pubitemid 26237169)
7. Pirko I, Johnson AJ, Chen Y, et al. Brain atrophy correlates with functional outcome in a murine model of multiple sclerosis. Neuroimage 2011; 54:802-806.
8. Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts .5. year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1351-1356.
9. Charil A, Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 2007; 259:7-15. (Pubitemid 47031196)
10. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31:247-269.
11. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132:1175-1189.
12. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68:477-493.
13. Androdias G, Reynolds R, Chanal M, et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010; 68:465-476.
14. Mahad D, Lassmann H, Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008; 34: 577-589.
15. Witte ME, Geurts JJ, de Vries HE, et al. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 2010; 10:411-418.
16. Anderson JM, Patani R, Reynolds R, et al. Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol 2010; 119:591-600.
17. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69:83-89.
18. Sattler MB, Bahr M. Future neuroprotective strategies. Exp Neurol 2010; 225:40-47.
19. Petratos S, Azari MF, Ozturk E, et al. Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol 2010; 69:323-334.
20. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011; 93:1-12.
21. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5:343-354.
22. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606-616. (Pubitemid 43278223)
23. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129:595-605. (Pubitemid 43278222)
24. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133 (Pt 7):1900-1913.
25. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128:2705-2712. (Pubitemid 41552953)
26. Siffrin V, Radbruch H, Glumm R, et al. In vivo imaging of partially reversible TH17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010; 33:424-436.
27. Howell OW, Rundle JL, Garg A, et al. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 2010; 69:1017-1033.
28. Oksenberg JR, Baranzini SE. Multiple sclerosis genetics: is the glass half full, or half empty? Nat Rev Neurol 2010; 6:429-437.
29. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13:554-573. (Pubitemid 37420699)
30. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008; 131:288-303.
31. Dutta R, McDonough J, Chang A, et al. Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients. Brain 2007; 130:2566-2576. (Pubitemid 47511716)
32. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120 (Pt 3):393-399. (Pubitemid 27153632)
33. Petzold A, Gveric D, Groves M, et al. Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol 2008; 213:326-335.
34. SchirmerL,AlbertM,BussA,etal.Substantialearly,butnonprogressiveneuronal loss in multiple sclerosis (MS) spinal cord. Ann Neurol 2009; 66:698-704.
35. Schneider A, Araujo GW, Trajkovic K, et al. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J Biol Chem 2004; 279:55833-55839. (Pubitemid 40066591)
36. Anderson JM, Hampton DW, Patani R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008; 131:1736-1748. (Pubitemid 351957465)
37. Anderson JM, Patani R, Reynolds R, et al. Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol (Berl) 2009; 117:583-589.
38. Li S, Kuroiwa T, Ishibashi S, et al. Transient cognitive deficits are associated with the reversible accumulation of amyloid precursor protein after mild traumatic brain injury. Neurosci Lett 2006; 409:182-186. (Pubitemid 44648562)
39. Pesini P, Kopp J, Wong H, et al. An immunohistochemical marker for Wallerian degeneration of fibers in the central and peripheral nervous system. Brain Res 1999; 828:41-59. (Pubitemid 29236473)
40. Dziedzic T, Metz I, Dallenga T, et al. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010; 20:976-985.
41. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1:232-241. (Pubitemid 37159185)
42. Knoferle J, Koch JC, Ostendorf T, et al. Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci USA 2010; 107:6064-6069.
43. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59:478-489. (Pubitemid 43358068)
44. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008; 131:1722-1735. (Pubitemid 351957459)
45. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132:1161-1174.
46. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.Ann Neurol 2010 [Epub ahead of print].
47. Kovacs GG, Hoftberger R, Majtenyi K, et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005; 128:35-41. (Pubitemid 40070518)
48. Kim JY, Shen S, Dietz K, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 2010; 13:180-189.
49. Ciccarelli O, Toosy AT, De Stefano N, et al. Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 2010; 30:15030-15033.
50. Ciccarelli O, Altmann DR, McLean MA, et al. Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 2010; 74:721-727.
51. Rossi S, Muzio L, De Chiara V, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 2010 [Epub ahead of print].
52. Rossi S, De Chiara V, Furlan R, et al. Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 2010; 24:1379-1385.
53. Vercellino M, Merola A, Piacentino C, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007; 66:732-739. (Pubitemid 47344252)
54. Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67:960-967. (Pubitemid 44454585)
55. Centonze D, Muzio L, Rossi S, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29:3442-3452.
56. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010; 90:774-786.
57. Rico A, Zaaraoui W, Franques J, et al. Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction. MAGMA 2010. [Epub ahead of print] .
58. Dell'Acqua ML, Landi D, Zito G, et al. Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment. Hum Brain Mapp 2010; 31:1588-1600.
59. Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011; 134:571-584.
60. Stirling DP, Stys PK. Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation. Trends Mol Med 2010; 16:160-170.
61. Shindler KS, Ventura E, Dutt M, et al. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 2010; 30:328-339.
62. Yang Y, Liu Y, Wei P, et al. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol 2010; 67:498-507.
63. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133:2232-2247.
64. Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis: what are the targets for therapy. J Neurol Sci 2010. [Epub ahead of print] .
65. Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs 2010; 19:1603-1612.
66. Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 2010; 7:30.
67. Fancy SP, Kotter MR, Harrington EP, et al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol 2010; 225:18-23.